Table 3.
Confirmed stone former subgroup | IRRa (95% CI) (per 5-year change) |
P | Estimated Incidence Rate (95% CI) in 1984b |
Estimated Incidence Rate (95% CI) in 2012b |
Absolute change in Incidence Rate from 1984–2012b |
---|---|---|---|---|---|
Stone Diameter | |||||
≤3mm | 1.58 (1.52–1.65) | <.001 | 7 (6–9) | 99 (90–109) | 92 |
>3mm or unknown | 1.11 (1.08–1.13) | <.001 | 92 (86–99) | 162 (152–172) | 70 |
Stone location on imaging | |||||
Pelvic/Lower pole | 1.26 (1.19–1.34) | <.001 | 6 (5–8) | 24 (20–28) | 18 |
Ureteropelvic junction | 1.47 (1.35–1.60) | <.001 | 2 (1–3) | 21 (17–25) | 19 |
Ureterovesical junction | 1.29 (1.25–1.34) | <.001 | 19 (17–22) | 83 (76–91) | 64 |
Ureter | 1.24 (1.20–1.28) | <.001 | 26 (23–30) | 90 (82–98) | 64 |
Voided stone seen | 1.08 (1.06–1.11) | <.001 | 54 (49–59) | 85 (78–92) | 31 |
Infected stones | 1.15 (1.03–1.28) | .01 | 2 (1–4) | 6 (4–8) | 4 |
Stone Composition | |||||
Unknown | 1.28 (1.25–1.31) | <.001 | 37 (34–41) | 149 (139–159) | 112 |
COM | 1.11 (1.07–1.14) | <.001 | 38 (34–42) | 67 (61–73) | 29 |
COD | 0.96 (0.89–1.04) | .33 | 8 (6–10) | 6 (4–8) | −2 |
Hydroxyapatite | 1.24 (1.16–1.32) | <.001 | 6 (5–8) | 21 (18–25) | 15 |
Uric Acid | 0.94 (0.84–1.05) | .24 | 4 (3–6) | 3 (2–4) | −1 |
Adjusted rates calculated using the age and sex distribution of the US 2010 census
Incidence rate per